FIZE Medical Secures $30 Million in Series A Funding to Drive Innovations in Fluid Management Technology Culminating in a $14 Million Series A-4 Round Led by Rapha Capital Management

FIZE Medical获得3000万美元的A系列资金，以推动流体管理技术的创新，最终在Rapha Capital Management领导的1400万美元的A-4系列融资中达到顶峰

• FIZE-kUO® groundbreaking device, anchoring FIZE's fluid management platform technology, detects early signs of kidney deterioration

•FIZE kUO®开创性设备，锚定FIZE的流体管理平台技术，可检测肾脏恶化的早期迹象

• Integrated with FIZE's AI-enabled algorithms, FIZE's fluid management technology allows real-time treatment adjustments to prevent long-term kidney damage and improve patient outcomes.

•与FIZE的人工智能算法相结合，FIZE的液体管理技术可以进行实时治疗调整，以防止长期肾脏损伤并改善患者预后。

WILMINGTON, Del., January 14, 2025-- FIZE Medical, a leader in fluid management optimization, is excited to announce the successful closure of its $30 million Series A funding round, including a $14 million Series A-4 round led by Rapha Capital Management and its managed fund, Rapha Capital PE Life Sciences Fund VI..

威尔明顿，Del。，2025年1月14日——流体管理优化领域的领导者FIZE Medical很高兴地宣布其3000万美元的a轮融资成功结束，其中包括由Rapha Capital management及其管理基金Rapha Capital PE Life Sciences fund VI领导的1400万美元的a-4轮融资。。

FIZE Medical is a commercial-stage company, solidifying its position as a pioneer in smart fluid management technology by expanding its geographical reach to the U.S., EU, and Asian markets. The company is also advancing its technological development and is set to soon launch AI-based predictive capabilities that will serve as a Decision Support System (DSS) by means of advanced data analysis.

FIZE Medical是一家商业舞台公司，通过将其地理范围扩展到美国、欧盟和亚洲市场，巩固了其作为智能流体管理技术先驱的地位。该公司还在推进其技术开发，并将很快推出基于人工智能的预测功能，该功能将通过先进的数据分析作为决策支持系统（DSS）。

The market for AI-based technologies in critical care is currently estimated at approximately $12 billion annually..

基于人工智能的重症监护技术市场目前估计每年约为120亿美元。。

Superior Technology

卓越的技术

Managing the hemodynamic status of critically ill patients is a major challenge for intensive care teams, as inaccurate diagnosis leading to misguided treatment can lead to severe complications and is a leading cause of mortality in intensive care units. In the United States alone, over 4 million patients are hospitalized annually in intensive care units, with more than one-third experiencing circulatory shock, which carries a mortality rate of approximately 40%..

管理重症患者的血流动力学状态是重症监护团队面临的主要挑战，因为不准确的诊断导致误导治疗可能导致严重的并发症，并且是重症监护病房死亡的主要原因。仅在美国，每年就有400多万患者在重症监护病房住院，超过三分之一的患者出现循环性休克，死亡率约为40%。。

Additionally, around 50% of ICU patients develop AKI (Acute Kidney Injury) during hospitalization, resulting in mortality rates exceeding 20%. Early detection of AKI and Shock may significantly reduce morbidity and mortality rates.

此外，大约50%的ICU患者在住院期间发生AKI（急性肾损伤），导致死亡率超过20%。早期发现AKI和休克可能会显着降低发病率和死亡率。

The company's technology meets these challenges with digital, continuous and real-time monitoring of kidney output. The data is streamed, minute by minute in real-time to a bedside device and the patient's electronic medical record (EMR), providing proactive never before available, accurate data of changes in kidney function to the medical team, alerting them to important events when they are determined by the FIZE kUO 'smart' device.

。数据实时逐分钟传输到床边设备和患者的电子病历（EMR），为医疗团队提供前所未有的主动准确的肾功能变化数据，当FIZE kUO“智能”设备确定重要事件时，提醒他们注意重要事件。

By helping medical teams adjust therapies promptly, FIZE Medical's groundbreaking innovation simplifies clinical decision-making , enables improved patient outcomes, aims to reduce mortality, and alleviates the workload on healthcare professionals..

通过帮助医疗团队及时调整治疗方法，FIZE medical的开创性创新简化了临床决策，改善了患者预后，旨在降低死亡率，减轻了医疗保健专业人员的工作量。。

Commercial Momentum

商业动力

The company saw an impressive surge in demand in 2024, driving rapid development and operational growth. Sima Faifman Kuchersky, FIZE Medical's Chief Commercial Officer, noted: 'In response to the growing demand across both domestic and international markets, we have strategically expanded our production capabilities—strengthening internal operations while leveraging our partnership with Cicor facilities in Vietnam to ensure scalability and efficiency.'.

2024年，该公司的需求激增，推动了公司的快速发展和运营增长。FIZE Medical首席商务官Sima Faifman Kuchersky指出：“为了应对国内外市场日益增长的需求，我们战略性地扩大了生产能力，加强了内部运营，同时利用我们与Cicor在越南的合作伙伴关系，确保可扩展性和效率。”。

A-4 Funding Round

A-4融资回合

Over the next year, FIZE Medical plans to expand its platform to include advanced AI-driven patient condition predictions, intra-abdominal pressure measurement, and additional features aimed at enhancing patient care.

明年，FIZE Medical计划扩展其平台，以包括先进的人工智能驱动的患者状况预测，腹内压测量以及旨在增强患者护理的其他功能。

The Series A-4 financing was led by Rapha Capital Management, founded by its President, Kevin Slawin, M.D., a successful and experienced urologist, domain experts on the 'best practice' for maintaining kidney health and Foley catheter management, oncologic and robotic surgeon, who is now focusing now on advancing disruptive healthcare technologies.

A-4系列融资由Rapha Capital Management牵头，Rapha Capital Management由总裁Kevin Slawin医学博士创建，Kevin Slawin是一位成功且经验丰富的泌尿科医生，是维持肾脏健康和Foley导管管理“最佳实践”领域专家，肿瘤学和机器人外科医生，目前正专注于推进颠覆性医疗保健技术。

.

.

Joining this round is Valitas Venture Capital, known for its innovative approach to go-to-market strategies in the healthcare sector. Valitas Co-Founder and former Medtronic executive Tal Shnider will join FIZE Medical's board as an observer, bringing valuable expertise in MedTech and commercialization..

瓦利塔斯风险投资公司（Valitas Venture Capital）也加入了这一轮投资，该公司以其在医疗保健领域的创新上市策略而闻名。Valitas联合创始人、前美敦力高管Tal Shnider将以观察员身份加入FIZE Medical董事会，为医疗技术和商业化带来宝贵的专业知识。。

Also participating in the round is eHealth Ventures, a strategic investor that provides access to global distribution channels, connections with key opinion leaders (KOLs), and a robust commercial network. Yair Hadar, representing eHealth Ventures, will join FIZE Medical's board as an observer. eHealth Ventures' involvement will play a critical role in accelerating FIZE Medical's expansion into the U.S.

eHealth Ventures也参与了这一回合，它是一家战略投资者，提供全球分销渠道、与关键意见领袖（KOL）的联系以及强大的商业网络。代表eHealth Ventures的Yair Hadar将作为观察员加入FIZE Medical的董事会。eHealth Ventures的参与将在加速FIZE Medical向美国的扩张中发挥关键作用。

market while reinforcing its leadership in smart fluid management technology..

市场，同时加强其在智能流体管理技术方面的领先地位。。

Dror Zerem, CEO of FIZE Medical, commented:

FIZE Medical首席执行官Dror Zerem评论道：

'We are thrilled to have Rapha Capital as the lead investor in this funding round, reaffirming their commitment to our mission. This funding, alongside support from Valitas Venture Capital, eHealth Ventures, and our existing investors, will enable us to accelerate our expansion into the U.S. and EU healthcare markets.

“我们很高兴Rapha Capital成为这轮融资的主要投资者，重申了他们对我们使命的承诺。这笔资金，加上Valitas风险投资公司、eHealth Ventures和我们现有投资者的支持，将使我们能够加速向美国和欧盟医疗市场的扩张。

With our innovative fluid management solutions, we look forward to positively impacting more hospitals and patients globally.'.

凭借我们创新的液体管理解决方案，我们期待着对全球更多的医院和患者产生积极影响。”。

FIZE Medical Mission

FIZE医疗任务

FIZE-kUO® strives to empower clinicians with real-time, actionable data at their fingertips, enabling next-generation, AI-powered fluid management. The company consistently pushes the boundaries of fluid management technology, revolutionizing patient care and improving medical efficiencies worldwide..

FIZE kUO®致力于为临床医生提供实时、可行的数据，实现下一代人工智能流体管理。该公司一直在推动液体管理技术的发展，彻底改变患者护理，提高全球医疗效率。。

To learn more please visit fizemedical.com

要了解更多信息，请访问fizemedical.com

About Rapha Capital Management, LLC

关于Rapha Capital Management，LLC

Rapha Capital Management, LLC is an investment advisory firm focused on making strategic investments in early stage, non-public biotechnology companies, through special purpose, joint venture entities (SPVs), which it manages. Rapha Capital was founded by its President, Kevin Slawin, M.D., a successful and experienced urologist, oncologic and robotic surgeon focusing now on disruptive healthcare technologies.

Rapha Capital Management，LLC是一家投资咨询公司，专注于通过其管理的特殊目的合资实体（SPV）对早期非上市生物技术公司进行战略投资。Rapha Capital由总裁凯文·斯莱温（KevinSlawin，M.D.）创立，他是一位成功且经验丰富的泌尿科医生、肿瘤学家和机器人外科医生，目前专注于颠覆性医疗保健技术。

Previously, he was the founder of Bellicum Pharmaceuticals, Inc., the very first CAR-T cell company, which he took public in 2014 with a $55 million crossover Series C and a successful $161 million IPO in December 2014. .

此前，他是Bellicum Pharmaceuticals，Inc.的创始人，Bellicum Pharmaceuticals，Inc.是第一家CAR-T细胞公司，他于2014年以5500万美元的crossover Series C上市，并于2014年12月成功完成了1.61亿美元的IPO。

After leaving Bellicum, he founded Rapha Capital Management, LLC (https://raphacap.com), which offers alternative asset management services to Rapha's fifteen SPVs, Rapha Capital Investment I to XV, LLC, as well as to its private equity fund, Rapha Capital PE Life Sciences Fund VI, which is the current vehicle for all investments managed by Rapha Capital Management..

离开Bellicum后，他成立了Rapha Capital Management，LLC(https://raphacap.com)，该公司为Rapha的15家特殊目的公司Rapha Capital Investment I to XV，LLC及其私募股权基金Rapha Capital PE Life Sciences fund VI（Rapha Capital management管理的所有投资的当前工具）提供替代资产管理服务。。

For more information about Rapha Capital Management, email info@raphacapital.com or visit https://raphacap.com

有关Rapha Capital Management的更多信息，请发送电子邮件info@raphacapital.com或访问https://raphacap.com

Contact:

联系人：

Eran Blankenstein

他们是布兰肯斯坦

eranblank@fizemedical.com

eranblank@fizemedical.com